Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary
Source: SeekingAlpha
2025-05-20 09:10:00 ET
Summary
- The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.
- Positioning in biotechnology weighed on relative returns, while an underweight to life sciences tools and services contributed to performance.
- Despite near-term healthcare policy uncertainty, we believe the sector’s innovation remains intact and that its defensive qualities will continue to appeal to investors.
...
Read the full article on Seeking Alpha
For further details see:
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.35% G/L:
$53.39 Last:
575,994 Volume:
$57.06 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
